1-3 of 3
Min Luo, PhD
Close
Sort by
Journal Articles

Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown, β-Globin Induction and Simultaneous Repression of β-Globin for the Potential Treatment of Sickle Cell Disease

Olivier Negre, PhD, Christian Brendel, PhD, Geoffrey B. Parsons, Min Luo, PhD, Myriam A Armant, PhD, Swaroopa Guda, PhD, Lauryn Christiansen, Gretchen Lewis, BMBS, Gabor Veres, PhD, Melissa Bonner, PhD, David A. Williams, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3557.
https://doi.org/10.1182/blood.V130.Suppl_1.3557.3557
Published: 2017
Journal Articles

Bone Marrow Characterization in Sickle Cell Disease: Inflammation and Stress Erythropoiesis Lead to Suboptimal CD34 Recovery Compared to Normal Volunteer Bone Marrow

Alexis Leonard, MD, Aylin Bonifacino, MS, Venina Marcela Dominical, PhD, Anna Conrey, NP, Wynona Coles, Mary Link, RN, Matthew Hsieh, MD, Min Luo, PhD, Naoya Uchida, MD PhD, Francis J. Pierciey, Jr., John F Tisdale, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 966.
https://doi.org/10.1182/blood.V130.Suppl_1.966.966
Published: 2017
Journal Articles

DOT1L As a Therapeutic Target for the Treatment of DNMT3A -Mutant Acute Myeloid Leukemia

Rachel E. Rau, MD, Min Luo, PhD, Benjamin Rodriguez, PhDBA, Mira Jeong, PhD, Allison Rosen, M.S., Lishing Deng, Yongcheng Song, PhD, Margaret A Goodell, PhD
Journal: Blood
Blood (2014) 124 (21): 614.
https://doi.org/10.1182/blood.V124.21.614.614
Published: 2014